The Need to Define Treatment Goals for Protein-Losing Enteropathy in Fontan Care and Research
(1) would have been overestimated because the effect on the surrogate, although statistically significant, was not of sufficient size and duration (mean change in albumin level 1.50 ± 1.03 g/dl, need for several procedures, duration of 4 months) in those patients with a treatment effect to predict a...
Saved in:
Published in | Journal of the American College of Cardiology Vol. 70; no. 20; pp. 2602 - 2603 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
14.11.2017
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | (1) would have been overestimated because the effect on the surrogate, although statistically significant, was not of sufficient size and duration (mean change in albumin level 1.50 ± 1.03 g/dl, need for several procedures, duration of 4 months) in those patients with a treatment effect to predict a meaningful alteration in clinical outcome (1,3). [...]the results of liver lymphatic embolization should be interpreted with caution, because this surrogate endpoint can yield misleading conclusions. [...]the Central Illustration and Table 3 (1) are somewhat confusing. [...]the duodenum as the site of lymph leakage in Fontan patients with PLE has not been reported previously (1). |
---|---|
Bibliography: | SourceType-Other Sources-1 content type line 63 ObjectType-Correspondence-1 ObjectType-Commentary-2 |
ISSN: | 0735-1097 1558-3597 |
DOI: | 10.1016/j.jacc.2017.07.800 |